Eliquis (apixaban) is a direct oral anticoagulant inhibiting Factor Xa. It is the market-leading DOAC for stroke prevention in atrial fibrillation and VTE treatment, preferred for its favorable safety profile.
Eliquis selectively inhibits Factor Xa, preventing prothrombin-to-thrombin conversion and reducing fibrin clot formation. Requires no routine monitoring and has lower major bleeding risk than warfarin.
Annual revenue trajectory
Revenue of competing drugs in the same class
4 indications
All approved therapeutic uses
Eliquis is the #1 prescribed DOAC with ~50% market share. Superior safety profile (lower bleeding vs warfarin and rivaroxaban) has driven sustained share gains. Preferred in clinical guidelines globally.
Peak sales of $13-14B expected through 2025-2026 before generic entry. Patent litigation may delay generics to 2028.
| Drug | Company | Revenue |
|---|---|---|
| Xarelto (rivaroxaban) | J&J/Bayer | $7.0B |
| Pradaxa (dabigatran) | Boehringer Ingelheim | $2.0B |
| Savaysa (edoxaban) | Daiichi Sankyo | $0.3B |
Revenue figures from company annual reports (FY2023). Clinical trial data from ClinicalTrials.gov. Competitive intelligence from Evaluate Pharma World Preview 2024 and IQVIA MIDAS. Market analysis by Medifirm Intelledge Global.